Ingesting mescaline leads to significant changes in the urinary excretion of certain compounds, affecting both chemistry and psychology. In a sample of 100 participants, 85% reported altered emotional states, while 70% experienced visual enhancements. The pharmacology of this psychedelic highlights its interaction with the urinary system, influencing how substances are synthesized and excreted. Additionally, understanding these effects can inform pharmacy and medical practices regarding benzodiazepine derivatives, offering insights into their therapeutic potential and safety profiles.
Mescaline causes visual changes whose intensity depends on dose, with no clear line between abnormal sensation, illusions, and hallucinations. People who rarely reported seeing mental images when asked to imagine were more prone to hallucinate. After taking mescaline, all subjects reported fewer visual mental images, and this decline was more linked to drug dose than to how vivid their hallucinations were, even among those who said their actual vision barely changed. Control subjects showed no such drop in visual imagery.